Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Postmarket safety profile of suicide/self-injury for GLP-1 receptor agonist: a real-world pharmacovigilance analysis
Congqin Chen, Rijing Zhou, Fang Fu, et al.
European Psychiatry (2023) Vol. 66, Iss. 1
Open Access | Times Cited: 27

Showing 1-25 of 27 citing articles:

Exploration of the potential association between GLP-1 receptor agonists and suicidal or self-injurious behaviors: a pharmacovigilance study based on the FDA Adverse Event Reporting System database
Jianxing Zhou, You Zheng, Baohua Xu, et al.
BMC Medicine (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 31
Disproportionality Analysis From World Health Organization Data on Semaglutide, Liraglutide, and Suicidality
Georgios Schoretsanitis, Stefan Weiler, Corrado Barbui, et al.
JAMA Network Open (2024) Vol. 7, Iss. 8, pp. e2423385-e2423385
Open Access | Times Cited: 18
Glucagon-like Peptide-1 Receptor Agonists and Suicidal Ideation: Analysis of Real-Word Data Collected in the European Pharmacovigilance Database
Rosanna Ruggiero, Annamaria Mascolo, Angela Spezzaferri, et al.
Pharmaceuticals (2024) Vol. 17, Iss. 2, pp. 147-147
Open Access | Times Cited: 17
Exploring the association between suicidal thoughts, self-injury, and GLP-1 receptor agonists in weight loss treatments: Insights from pharmacovigilance measures and unmasking analysis
Amira Guirguis, Stefania Chiappini, GD Papanti P, et al.
European Neuropsychopharmacology (2024) Vol. 82, pp. 82-91
Open Access | Times Cited: 16
Impact of treatment with GLP‐1RAs on suicide attempts in adults persons with type 2 diabetes: A retrospective comparative effectiveness study based on a global TriNetX health research database
Mahmoud Nassar, Anoop Misra, Zachary T. Bloomgarden
Journal of Diabetes (2024) Vol. 16, Iss. 3
Open Access | Times Cited: 15
Neuropsychiatric adverse events associated with Glucagon-like peptide-1 receptor agonists: a pharmacovigilance analysis of the FDA Adverse Event Reporting System database
Wenchao Lu, Shihan Wang, Huilin Tang, et al.
European Psychiatry (2025) Vol. 68, Iss. 1
Open Access | Times Cited: 1
Association of glucagon-like peptide-1 receptor agonists with suicidal ideation and self-injury in individuals with diabetes and obesity: a propensity-weighted, population-based cohort study
Isabel Hurtado, Celia Robles, Salvador Peiró, et al.
Diabetologia (2024) Vol. 67, Iss. 11, pp. 2471-2480
Open Access | Times Cited: 8
Glucagon-Like Peptide-1 Receptor Agonists and Risk for Suicidal Ideation and Behaviors in U.S. Older Adults With Type 2 Diabetes
Huilin Tang, Ying Lü, William T. Donahoo, et al.
Annals of Internal Medicine (2024) Vol. 177, Iss. 8, pp. 1004-1015
Closed Access | Times Cited: 7
Risk of Suicide, Hair Loss, and Aspiration with GLP1-Receptor Agonists and Other Diabetic Agents: A Real-World Pharmacovigilance Study
Michael Nakhla, Ambica Nair, Prachi Balani, et al.
Cardiovascular Drugs and Therapy (2024)
Closed Access | Times Cited: 5
Antidepressants and Weight Gain: An Update on the Evidence and Clinical Implications
Lauren Moss, Marci Laudenslager, Kristine J. Steffen, et al.
Current Obesity Reports (2025) Vol. 14, Iss. 1
Closed Access
The Effect of Glucagon-Like Peptide-1 Receptor Agonists on Measures of Suicidality A Systematic Review
K.L. Valentino, Kayla M. Teopiz, William W. L. Cheung, et al.
Journal of Psychiatric Research (2025) Vol. 183, pp. 112-126
Open Access
Association of GLP‐1 Receptor Agonists With Risk of Suicidal Ideation and Behaviour: A Systematic Review and Meta‐Analysis
Ganesh Bushi, Mahalaqua Nazli Khatib, Shivam Rohilla, et al.
Diabetes/Metabolism Research and Reviews (2025) Vol. 41, Iss. 2
Open Access
An analysis on the role of glucagon-like peptide-1 receptor agonists in cognitive and mental health disorders
Riccardo De Giorgi, Ana Ghenciulescu, Oliwia Dziwisz, et al.
Nature Mental Health (2025)
Open Access
Assessing the safety of topical minoxidil through disproportionality analysis of FAERS reports
Yanbo Li, Bo Liu, Wei Wu, et al.
Expert Opinion on Drug Safety (2025)
Closed Access
Silexan is well-tolerated for long-term use in adults and for treatment of adolescents: a real-world data analysis
Hans‐Peter Volz, Thomas Rosemann, Martin Burkart, et al.
European Archives of Psychiatry and Clinical Neuroscience (2025)
Open Access
Conducting a real-world study of Tumor Necrosis factor-alpha inhibitors-induced Systemic Lupus Erythematosus based on the FAERS database
Mengjiao He, Jiale Yang, Simin Yan, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access
Risk of depression and dementia among individuals treated with sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists
Osvaldo P. Almeida
Current Opinion in Psychiatry (2025)
Closed Access
A post-marketing disproportionality analysis of the safety of ribociclib based on the FDA Adverse Event Reporting System
Jing Xu, Ruo Wang, Kunwei Shen
Therapeutic Advances in Drug Safety (2025) Vol. 16
Open Access
Suicide and Self-Harm Events With GLP-1 Receptor Agonists in Adults With Diabetes or Obesity
Pouya Ebrahimi, Juan C. Batlle, Aryan Ayati, et al.
JAMA Psychiatry (2025)
Closed Access
Pharmacovigilance study of GLP-1 receptor agonists for metabolic and nutritional adverse events
Long He, Qiuyu Li, Yongfeng Yang, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 2
Comparative analysis of semaglutide induced adverse reactions: Insights from FAERS database and social media reviews with a focus on oral vs subcutaneous administration
Jing Zhang, Wang Xiao-fen, Yiting Zhou
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 2
Semaglutide for management of obesity in adolescents: efficacy, safety, and considerations for clinical practice
Megan O. Bensignor, Silva Arslanian, Mary Ellen Vajravelu
Current Opinion in Pediatrics (2024) Vol. 36, Iss. 4, pp. 449-455
Closed Access | Times Cited: 1
Newer glucose‐lowering drugs and risk of suicidal ideation and behaviours: A network meta‐analysis of randomized outcome trials
Ying Lü, Huilin Tang, Pareeta Kotecha, et al.
Diabetes Obesity and Metabolism (2024) Vol. 26, Iss. 10, pp. 4783-4786
Closed Access | Times Cited: 1
Pharmacological management of pediatric metabolic dysfunction‐associated steatotic liver disease
Rasha Abi Radi Abou Jaoudeh, Phillipp Hartmann, Oakley C. Olson, et al.
Journal of Pediatric Gastroenterology and Nutrition (2024)
Closed Access | Times Cited: 1
Central nervous system stimulants and drugs that suppress appetite
Elif Ece Akgün, Mehmet Uzumcu, Nicholas T. Bello
Side effects of drugs annual (2024), pp. 547-561
Closed Access
Page 1 - Next Page

Scroll to top